Aquino, 'Transfer of Chirality to Metal Centers: A Novel Approach', 94th Canadian Chemistry Conference and Exhibition, Montreal, PQ, June 5-9, 2011. Aquino, 'The Effect of Phenyl Ring Position on Hydrocarbon Chains of Potential Diruthenium Liquid Crystals', 37th Annual Science Atlantic/CIC Student Chemistry Conference, Cape Breton University, May 15-17, 2012. Aquino, 'Transfer of Chirality from Ligand to Metal Center: A New Methodology', 96th Canadian Chemistry Conference and Exhibition, Quebec City, PQ, May 26-30, 2013. Aquino, 'Structure-Function Correlations in Mixed-Valent Diruthenium (II,III) Tetraacetate Complexes Containing Various Axially-Bound Pyridine Derivatives', 99th Canadian Chemistry Conference and Exhibition, Halifax, NS, June 4-8, 2016. Stanley Cameron, Dieter Klapstein and Manuel A.S. Regular Conference Presentations (by myself, students or collaborators)Ħ7. “The Active Site Chemistry of the Binuclear Iron Enzyme Purple Acid Phosphatase”, Inorganic Mechanisms Discussion Group Meeting, University of Warwick, Coventry, UK, December 15, 1992. “Bridge Mediated Metal-Metal Interactions: To Couple or Not to Couple”, Department of Chemistry, Dalhousie University, Halifax, Nova Scotia, March 24, 1995.ġ. “Dimetal Carboxylates: Building Blocks for Molecular Wires, Switches and Liquid Crystals”, Department of Chemistry, Acadia University, Wolfville, Nova Scotia, January 25, 1996.Ģ. Mary’s University, Halifax, Nova Scotia, March 15, 1996.ģ. “Molecular Wires and Polymeric Liquid Crystals Incorporating Dimetal Carboxylates”, Department of Chemistry, St. Francis Xavier University, Antigonish, Nova Scotia, May 15-17, 1996.Ĥ. “Inorganic Materials: A Coordination Chemist’s Perspective”, Honourary Guest Lecture, 1996 CIC-APICS Atlantic Student Chemistry Conference, St. “Synthesis and Properties of Mixed-Valent Diruthenium(II,III) tetrametallocenecarboxylates”, 34 th International Conference on Coordination Chemistry, Edinburgh, Scotland, July 9-14, 2000.ĥ. “The Many Faces of Diruthenium Carboxylate Chemistry”, Department of Chemistry, Dalhousie University, Halifax, Nova Scotia, September 30, 2000.Ħ. “The Many Faces of Diruthenium Carboxylate Chemistry”, Atlantic CIC Tour Speaker, Acadia University, Wofville, Nova Scotia University of New Brunswick, Fredericton, New Brunswick Mount Allison University, Sackville, New Brunswick. Mary’s University, Halifax, Nova Scotia, September 10, 2004.Ĩ. “Reaction of Diruthenium(II,III) Tetracarboxylate with p-Acids: Adventures in Dimer Disassembly”, Department of Chemistry, St.

“Some Novel Aspects of Diruthenium(II,III) Tetracarboxylate Chemistry”, Department of Chemistry, Dalhousie University, Halifax, Nova Scotia, October 8, 2005.ĩ. 'Chiral Induction at Ru(II): A Novel Approach', Department of Chemistry, Dalhousie University, Halifax, Nova Scotia, September 13, 2013.ġ0. 'A New Methodology for the Chirality Induction/Transfer at Ru(II)', Department of Chemistry, Mount Allison University, Sackville, New Brunswick, October 6, 2014.ġ1. Remdesivir in combination with baricitinib for the treatment of COVID-19, was granted an FDA Emergency Use Authorization on November 19, 2020.12. Remdesivir was also approved by the European Commission on July 3, 2020.

Remdesivir is currently marketed under the trademark name VEKLURY by Gilead Sciences Inc. Remdesivir was confirmed as a non-obligate chain terminator of RdRp from SARS-CoV-2 and the related SARS-CoV and MERS-CoV, and has been investigated in multiple COVID-19 clinical trials.Īfter initially being granted an FDA Emergency Use Authorization (EUA) on May 1st, 2020, remdesivir was fully approved by the FDA for the treatment of COVID-19 on October 22, 2020. Remdesivir activity against the Coronaviridae family was first demonstrated in 2017, leading to considerable interest in remdesivir as a possible treatment for COVID-19. Broad antiviral activity of remdesivir is suggested by its mechanism of action, and to date, it has demonstrated in vitro activity against the Arenaviridae, Flaviviridae, Filoviridae, Paramyxoviridae, Pneumoviridae, and Coronaviridae viral families.

Remdesivir (GS-5734) is an adenosine triphosphate analogue first described in the literature in 2016 as a potential treatment for Ebola.

Like other RNA viruses, SARS-CoV-2 depends on an RNA-dependent RNA polymerase (RdRp) enzyme complex for genomic replication, which can be inhibited by a class of drugs known as nucleoside analogues. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19), which is a respiratory disease that is capable of progressing to viral pneumonia and acute respiratory distress syndrome (ARDS) COVID-19 can be fatal.

Fx chem 2.006